Although early in their clinical development, it is tempting to speculate that the universal mechanism of action of anti-CTLA-4, anti-PD-1, and CD40 or OX-40 agonists, among other molecules, may not only be restricted to melanoma patients but rather may be useful in a wide range of other oncologic diseases. The gene discussed is CTLA4; the disease is melanoma.